Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CRHBP | P24387 | 1/20 | 0.41 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 4/20 | 0.39 |
| ▸ | DRD3 | P35462 | 3/20 | 0.39 |
| ▸ | DRD1 | P21728 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | DRD5 | P21918 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 3/20 | 0.38 |
| ▸ | CA2 | P00918 | 3/20 | 0.38 |
| ▸ | CA9 | Q16790 | 3/20 | 0.38 |
| ▸ | CA5A | P35218 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31272156 | 1.00 | ALDH1A1 (0.42) | ALDH1A1ADRA2BPTGS1TDP1KDM4E | |
| SCHEMBL1712875 | 0.86 | DRD2 (0.43) | ALDH1A1DRD2DRD3DRD1DRD4 | |
| SCHEMBL17310208 | 0.84 | DRD2 (0.36) | KDM4EMAPTCRHBPCRHR2DRD2 | |
| SCHEMBL6812319 | 0.82 | ALDH1A1 (0.43) | ALDH1A1TDP1DRD2DRD3DRD1 | |
| SCHEMBL7023211 | 0.80 | DRD2 (0.42) | ALDH1A1KDM4EMAPTDRD2DRD3 | |
| SCHEMBL16926997 | 0.78 | DRD2 (0.41) | KDM4EMAPTDRD2DRD3DRD1 | |
| SCHEMBL776669 | 0.78 | DRD2 (0.40) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL6937413 | 0.78 | HSD11B1 (0.50) | ALDH1A1KDM4EMAPTDRD2DRD3 | |
| SCHEMBL22475388 | 0.78 | ELANE (0.59) | ALDH1A1ADRA2BPTGS1TDP1KDM4E | |
| SCHEMBL9396334 | 0.77 | ALDH1A1 (0.50) | ALDH1A1ADRA2BPTGS1TDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118271364-A | 3, 5-Dialkyl-4- (disubstituted phosphino) -1-alkyl-1H-pyrazole and preparation method and application thereof | 香港理工大学深圳研究院 | 2024-07-02 | — | — | CN | disclosed |
| US-20240018125-A1 | CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS | ERMIUM THERAPEUTICS (FR) | 2024-01-18 | — | — | US | disclosed |
| WO-2023214552-A1 | TRIFLUOROMETHANE SULFONYLATION AGENT COMPOSITION AND METHOD FOR PRODUCING TRIFLUOROMETHANESULFONYLOXY COMPOUND OR TRIFLUOROMETHANE SULFONYL COMPOUND | セントラル硝子株式会社 | 2023-11-09 | — | — | WO | disclosed |
| EP-4217353-A1 | CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS | Ermium Therapeutics (FR) | 2023-08-02 | — | — | EP | disclosed |
| CN-114394933-A | Method for synthesizing 11, 12-dihydro-gamma-oxo-dibenzo [ [ F ] azo-5- (6H) -butyric acid | 厦门沃克沃德医药科技有限公司 | 2022-04-26 | — | — | CN | disclosed |
| WO-2022064075-A1 | CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS | ERMIUM THERAPEUTICS (FR) | 2022-03-31 | — | — | WO | disclosed |
| US-7479496-B2 | Substituted spiro azabicyclics as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-20 | — | — | US | disclosed |
| US-7230022-B2 | Substituted fused bicyclic amines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-06-12 | — | — | US | disclosed |
| US-7122547-B1 | Anthranilic acid amides and the use thereof as medicaments | SCHERING AG (DE) | 2006-10-17 | — | — | US | disclosed |
| US-7081468-B2 | Ortho-substituted anthranilic acid amides and their use as medicaments | SCHERING AG (DE) | 2006-07-25 | — | — | US | disclosed |
| CN-1237062-C | Ortho-substituted anthranilic acid amides and their use as medicaments | SCHERING AG (DE) | 2006-01-18 | — | — | CN | disclosed |
| US-20050197373-A1 | Substituted fused bicyclic amines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2005-09-08 | — | — | US | disclosed |
| US-20050197325-A1 | Substituted spiro azabicyclics as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2005-09-08 | — | — | US | disclosed |
| US-6919356-B2 | N-substituted heterocyclic amines as modulators of chemokine receptor activity | BRISTOL MYERS SQUIBB COMPANY (US) | 2005-07-19 | — | — | US | disclosed |
| US-20040102441-A1 | Ortho-substituted anthranilic acid amides and their use as medicaments | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-05-27 | — | — | US | disclosed |
| CN-1151133-C | Anthranilic acid amides and the use thereof as medicaments | ���ֹɷݹ�˾ | 2004-05-26 | — | — | CN | disclosed |
| US-20040067935-A1 | N-substituted heterocyclic amines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-08 | — | — | US | disclosed |
| CN-1427837-A | Ortho-substituted anthranilic acid amides and their use as medicaments | SCHERING AG (DE) | 2003-07-02 | — | — | CN | disclosed |
| CN-1325384-A | Anthranilic acid amides and the use thereof as medicaments | SCHERING AG (DE) | 2001-12-05 | — | — | CN | disclosed |
| US-5877329-A | Palladium catalyzed indolization | MERCK & CO., INC. (US) | 1999-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197325-A1 | Substituted spiro azabicyclics as modulators of chemokine receptor activity | CCR3, CCR1, CCR2 | ALDH1A1 749/4885ADRA2B 48/4885PTGS1 799/4885 |
| US-20240018125-A1 | CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS | CXCR4, CXCR1, CXCL12 | ALDH1A1 2260/4885ADRA2B 2097/4885PTGS1 421/4885 |
| US-20050197373-A1 | Substituted fused bicyclic amines as modulators of chemokine receptor activity | CCR3, CCR1, CCR2 | ALDH1A1 2021/4885ADRA2B 79/4885PTGS1 954/4885 |
| US-20040102441-A1 | Ortho-substituted anthranilic acid amides and their use as medicaments | TEK, VEGFA, ASPH | ALDH1A1 1414/4885ADRA2B 742/4885PTGS1 342/4885 |
| US-20040067935-A1 | N-substituted heterocyclic amines as modulators of chemokine receptor activity | CCL11, ACKR3, CCR7 | ALDH1A1 536/4885ADRA2B 135/4885PTGS1 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.